What is Ocrevus?
Ocrevus (ocrelizumab) is a prescription medication used to treat Relapse-Remitting Multiple Sclerosis (RRMS) or Primary Progressive Multiple Sclerosis (PPMS). It has been shown in clinical trials to decrease relapses in people with RRMS and to slow disease progression in people with PPMS. Ocrevus is the only FDA-approved prescription medication for PPMS.
How does Ocrevus work?
Ocrevus is an anti-CD20 monoclonal antibody designed to target and eliminate mature B cells, a type of immune system cell that damages nerve cells in people with MS. Ocrevus is initially given as two intravenous (IV) infusions two weeks apart, followed by a single infusion every six months. IV infusions are given in the doctor’s office.